Showing 5501-5510 of 6035 results for "".
- Johnson & Johnson Vision Launches Tecnis Eyhance Monofocal IOL in Indiahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-eyhance-monofocal-iol-in-india/2477059/Johnson & Johnson Vision announced the launch of Tecnis Eyhance IOL, which is designed to extend depth of focus from distance to intermediate vision. Over the past several decades, India’s eye care system has made tremendous strides towards high q
- Manufacturers, Providers Increasingly Rely on Premium Cataract Surgery Revenuehttps://modernod.com/news/manufacturers-providers-increasingly-rely-on-premium-cataract-surgery-revenue/2477057/The importance of premium cataract surgery to manufacturers, surgeons, and surgery centers alike grows, as reimbursements for cataract surgery under nationalized health care systems worldwide continue to decline, according to a Market Scope report. The reduction in cataract surgery reimbur
- Eyenovia Advances MicroLine for the Treatment of Presbyopia; Reprioritizes Late-Stage Ophthalmology Pipelinehttps://modernod.com/news/eyenovia-advances-microline-for-the-treatment-of-presbyopia-reprioritizes-late-stage-ophthalmology-pipeline/2477052/Eyenovia announced that the company is advancing the development of its MicroLine program for the improvement in near vision in patients with presbyopia toward phase 3 development. As a result of prioritizing MicroLine in tandem with its MicroPine (progressive myopia) and MicroSta
- Iveric bio Appoints Abraham Scaria, PhD, as Chief Scientific Officerhttps://modernod.com/news/iveric-bio-appoints-abraham-scaria-phd-as-chief-scientific-officer/2477050/Iveric bio announced the appointment of Abraham Scaria, PhD, to the position of Chief Scientific Officer, effective October 29, 2019. Dr. Scaria will lead the company’s research and preclinical gene therapy activities. Dr. Scaria’s extensive experience includes positions at Genzyme, Sanofi, and m
- NovaBay Pharmaceuticals to Distribute the NuLids System for the Treatment of Dry Eye in Certain U.S. Geographieshttps://modernod.com/news/novabay-pharmaceuticals-to-distribute-the-nulids-system-for-the-treatment-of-dry-eye-in-certain-u-s-geographies/2477048/NovaBay Pharmaceuticals announced an exclusive 90-day agreement with NuSight Medical to distribute the NuLids System for treatment of blepharitis and dry eye in six of NovaBay’s top-performing territories. The NuLids System is a hand-held, cordless device that safely and effectively removes accum
- Iveric bio’s Zimura Meets its Primary Endpoint in a Phase 2b Trial in Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/iveric-bios-zimura-meets-its-primary-endpoint-in-a-phase-2b-trial-in-geographic-atrophy-secondary-to-dry-amd/2477046/Iveric bio announced initial topline data confirming that Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, met its prespecified primary endpoint in reducing the rate of geographic atrophy (GA) growth in patients with dry age-related macular degeneration (AMD) in a random
- Secondhand Smoke May Damage Children’s Eyeshttps://modernod.com/news/secondhand-smoke-may-damage-childrens-eyes/2477043/Secondhand smoke may damage children’s eyes and possibly lead to problems with sight later in life, new findings suggest. In a study of Chinese children, increasing exposure to secondhand smoke was associated with choroidal th
- More Evidence Links Common Bladder Drug to Retinal Damagehttps://modernod.com/news/more-evidence-links-common-bladder-drug-to-retinal-damage/2477044/Pentosan polysulfate sodium (PPS), used widely for interstitial cystitis, may lead to retinal damage, according to a new study that adds weight to this previously suggested link, as reported by Reuters. Interstitial cystitis causes
- Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Clinical Trial of Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-doses-first-patient-in-third-cohort-of-optic-phase-1-clinical-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2477039/Adverum Biotechnologies announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1 clinical trial for ADVM-022 for the treatment of neovascular age-related macular degeneration (AMD). Patients in this cohort are receiving a single intravitreal injection of g
- Oculus Teams Up With BHVI to Improve Myopia Managementhttps://modernod.com/news/oculus-teams-up-with-bhvi-to-improve-myopia-management/2477036/Oculus and BHVI (Brien Holden Vision Institute) have announced an agreement that will allow Oculus to incorporate BHVI’s algorithms for tracking and estimating refractive error into its Myopia Master ophthalmic instruments developed for the management of myopia.